0000000000-11-011392.txt : 20110408
0000000000-11-011392.hdr.sgml : 20110408
20110222171703
ACCESSION NUMBER: 0000000000-11-011392
CONFORMED SUBMISSION TYPE: UPLOAD
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20110222
FILED FOR:
COMPANY DATA:
COMPANY CONFORMED NAME: Celldex Therapeutics, Inc.
CENTRAL INDEX KEY: 0000744218
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 133191702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: UPLOAD
BUSINESS ADDRESS:
STREET 1: 119 FOURTH AVE
CITY: NEEDHAM
STATE: MA
ZIP: 02494
BUSINESS PHONE: 7814330771
MAIL ADDRESS:
STREET 1: 119 FOURTH AVE
CITY: NEEDHAM
STATE: MA
ZIP: 02494-2725
FORMER COMPANY:
FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19980828
FORMER COMPANY:
FORMER CONFORMED NAME: T CELL SCIENCES INC
DATE OF NAME CHANGE: 19920703
PUBLIC REFERENCE ACCESSION NUMBER: 0001047469-10-002142
LETTER
1
filename1.pdf
begin 644 filename1.pdf
M)5!$1BTQ+C4-"B6UM;6U#0HQ(#`@;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#$O2VED'0O26UA9V5"+TEM86=E0R]);6%G94E=(#X^+TUE9&EA0F]X
M6R`P(#`@-C$R(#2]#4R]$979I8V521T(^/B]486)S+U,O4W1R
M=6-T4&%R96YT)R56%UOVS84?0^0
M_\!'"8@9?E,WGMX/TS./Y-W[\YOIS>7A+U_3SY<3LF'N].3\VM.N"!W\],33AC\<")M
M09DEECD*'SR>GC#R'?_[]?3D[XSD_Y"[CZE0HC6*4C\(S"><+
MLXO@=6ZR"HYTOX;S/.<3EY7PUSJ?<)/]EPN6P5$B9U324'$`=T8$XS%[PX[L
MX[:&*A':)L]K$SKA8J38BCB(=L5.;!,VL5VD
M%-3I<)=T1F()1UB^NQ6>*^Z_7.+)9_CX`W5-[A85\%^7X(HG?/O0>OGM?M@EQ`&%]\4/W-
MQ*>HK@I_4P*P-*6A]-Q34G)W8SY578J8+3#0CV>0^L#%^+S9O,8?_;5XWE1M
MNWU'`,>IF/^4HM*&VZ3))LJ`%HY:/0HEK`/R,,ERR#9,$,TUM;P#_(*G_R7F
M=#C'X8)H@(PXLITB>*?3_O[^`)WBS=E>(9653_TGS_C0P@73J->;!E..EVG,
MR\Y0X^+LCOVC![S<.X5QZL:><=_V.@9&1.7IYA2XF+1!;]&XF>-4\ZWH#R:S(RB7YJXKE,08U\`"]
M])A7>$F:(+3^@5QBT#%NU=8GD''NXKC1I4)^,1.8[K4#/0
MQ4H5!>5!K.IER/<61;CNQ>;=!*+PA3X:'\LP/P;8:89#Y;MG:"%9Q-3TED2"
MQ6]()+!%B9Q?C!&)3W>@%-D)1?VL`&"'^]YB5/RA-V(FI)OV[E!?TWL7FC+]
MT_'?,GPS_OO8:89#;4[/4)E=_CI@2#ZM*&$LRD-(RGB($!4!Y#GH>P);KADX
MNO\76P@]#'/APO1<],;8UM4U)27EH^J:2'07"EH5V:-XY?G^/IJ&N<&6)EAU
MZUNC-7:WL+3USJ^;:$TT4(Y#@#3YH3ZD*SH*+K$>AS+4('0HTO%=@^`;=2\=
MW\WX[HJ@L%>/3Z^R:JL9@0X,NUV\Y^N^'K_4U;]HOYJ37>\/A@0-YO6R;K['
MZH02F*P#*INHK:7:A;;1/EJS(UL\5S/S+>]L19I5"T?U`POQGP!SUTTM\W[F
M@V;3]\;^(%MO/+X.%.TFMGNG,6DM-O.[W5M(EK!Z46_P067U*UBL5^%P>V0(
ME(ZWBDM>&C7VX@PU/-V4C)Z%"7YONJH;/U'Y60JG/+[UXEDL38/ZE`QQTFP&
M9W80#K*!65N/0QDJI3V*@.%S',I0R>A16$'=$,J0%V.VQSL.E8!N1^$TY2-W
M#&P_^M2%PO/#*81NPD4G_B]^4*]FRVW=C011.YR4"L-"F5N9'-T7!E+T9O;G0O4W5B='EP92]4%=I9'1H(#(U-C@O
M1F]N=%=E:6=H="`T,#`O6$AE:6=H="`R-3`O3&5A9&EN9R`T,B]3=&5M5B`T
M,"]&;VYT0D)O>%L@+34V."`M,C$V(#(P,#`@-CDS72`^/@T*96YD;V)J#0HW
M(#`@;V)J#0H\/"]4>7!E+T9O;G0O4W5B='EP92]47!E+T9O;G1$97-C%=I9'1H(#$V,3@O1F]N=%=E:6=H="`T,#`O6$AE:6=H
M="`R-3`O3&5A9&EN9R`T,B]3=&5M5B`T,"]&;VYT0D)O>%L@+30Y."`M,C$V
M(#$Q,C`@-CDT72`^/@T*96YD;V)J#0HY(#`@;V)J#0H\/"]4>7!E+T9O;G0O
M4W5B='EP92]47!E+T9O;G1$
M97-C%=I9'1H(#(U-3@O1F]N
M=%=E:6=H="`W,#`O6$AE:6=H="`R-3`O3&5A9&EN9R`T,B]3=&5M5B`T,B]&
M;VYT0D)O>%L@+34U."`M,C$V(#(P,#`@-C"JZ3,KX63`9
M'1@UDS0R3-*1+&&$R9J1"B6,J%+*F&241^DK9D4D4RZ(%"I8`0/%$,%6JA`V
M4+$W8ZK)P*7:P%5J6-J,6D8D46N(9.P:8"NH.(558AZ1:JB8B`TRETH)QQ(V
MZH_T09PO]4,J*C@,3L;9;V^';0^-M!OVPW:X?Z+Q0,/VA;2/W=UM;JY$>#TB
MZQ%=C]AZ)*U'\GJDK$?J>J0%U$7T!OQR0#`'#'-`,0<<XX!G"7B6@&<)>):`9PEXEH!G"7C6@&<->-;(!R/@6:][EDMF/QUG?Z7[
M0+\0EM*6@BMA*>Q%O*@7\^+S\%U>2O'B%'&*.D6=HDY1IZA3U"GJ%'6*.D6=
M8DXQIYA3S"GF%'.*.<6<8DXQIR2GI(5RH(N/Q_/'-.SGT]=Q?CQ-T^[]?1ZV
MSZ?I;6G['=%E+1\'G_?GWX?I>[Z?SL07UL/7Z^=3OUKS[Q+_5>_FY@>=O+K(
M#0IE;F1S=')E86T-"F5N9&]B:@T*-3(@,"!O8FH-"EL@,C4P(#`@,"`P(#`@
M,"`P(#`@,"`P(#`@,"`R-3`@,"`R-3`@,"`U,#`@-3`P(#4P,"`P(#4P,"`P
M(#`@,"`P(#4P,"`R-S@@,"`P(#`@,"`P(#`@-S(R(#`@-C8W(#7!E+UA2968O4VEZ92`U
M-2]76R`Q(#0@,ET@+U)O;W0@,2`P(%(O26YF;R`Q,2`P(%(O241;/#DS-S4R
M-S8X,$0T-$%%-$4Y03DU,$,U03`U.3$T048T/CPY,S(J'(2.
M(U%R",[`8<+@#R[\9-FR9(OX:!KCLQ/YG8AY*>(*W$KV4F,GDIJ1')2M%
M`EU6PQXJ^/4.?M+:?V4@@!:TH0-=""&"&!)((0,+/